Aldoxorubicin may be safe, effective for advanced soft-tissue sarcoma
the ONA take:
Single-agent aldoxorubicin, a novel albumin-binding prodrug of doxorubicin, showed superior efficacy over doxorubicin and manageable adverse effects in patients with advanced soft-tissue sarcoma, a new study published online ahead of print in JAMA Oncology has shown.
For the international, multicenter, open-label, phase 2b study, researchers enrolled 126 patients with previously untreated locally advanced, unresectable, or metastatic soft-tissue sarcoma. Participants were randomly assigned 2:1 to receive aldoxorubicin 350 mg/m2 or doxorubicin 75 mg/m2 administered intravenously once every 3 weeks for up to six cycles.
Results showed that median progression-free survival was significantly improved with aldoxorubicin compared with doxorubicin. In addition, 6-month progression-free survival rates and tumor response rates were significantly improved with aldoxorubicin.
In regard to safety, no acute cardiotoxic effects were observed with either treatment, but left ventricular ejection fraction less than 50% occurred in 3 of 40 patients who received doxorubicin. Grade 3 or 4 neutropenia occurred more frequently in the aldoxorubicin group.
The findings suggest that further investigation of aldoxorubicin therapy in advanced soft-tissue sarcoma is warranted.
Single-agent aldoxorubicinshowed superior efficacy over doxorubicin and manageable adverse effects in advanced soft-tissue sarcoma.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- Screening Recommendations for Children with Common Cancer Predisposition Syndromes
- Significance of Prostate Cancer Treatment-Related Factors Differ in Black, White Men
- Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Lack of Transfusion Services a Barrier to Hospice Care for Patients With Blood Cancers
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Ethnic Differences, Cultural Barriers Negatively Impact Mammography Follow-up Among Asian Ethnic Groups
- Study Questions Safety of E-cigarettes vs Regular Tobacco Cigarettes
- Changes in Pulmonary Function Tests in Breast Carcinoma Patients Treated With Locoregional Post-mastectomy Radiotherapy: Results of a Pilot Study
- Increases in Liver Cancer Incidence Influenced by Higher Rates of Comorbidities
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|